Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06264440 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT06264440 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 18 participants.
The verdict
NCT06264440, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the effects of a proton pump inhibitor (PPI) \[rabeprazole\] on BIIB122 pharmacokinetics (PK) after a single dose in healthy participants. The secondary objective of the study is to evaluate the safety and tolerability of BIIB122, with and without a PPI (rabeprazole), after a single dose in healthy participants.
Interventions
- DRUG Rabeprazole
- DRUG BIIB122
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-02-12 |
| Est. Completion | 2024-06-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06264440
The ClinicalTrials.gov registry entry for NCT06264440 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rabeprazole is the first listed.
NCT06264440 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06264440 about?
NCT06264440 is a clinical study titled "A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants". The primary objective of the study is to evaluate the effects of a proton pump inhibitor (PPI) \[rabeprazole\] on BIIB122 pharmacokinetics (PK) after a single dose in healthy participants. The secondary objective of the study is to evaluate the safety and tolerability of BIIB122, with and without a ...
What is the current status of trial NCT06264440?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2024-02-12. Estimated completion is 2024-06-18.
What interventions are being tested in trial NCT06264440?
The interventions under investigation include: Rabeprazole (DRUG), BIIB122 (DRUG).
Who is sponsoring clinical trial NCT06264440?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.